Helius Price To Sales Ratio vs Free Cash Flow Per Share Analysis

HSDT Stock

USD 0.45 0.02 4.65%

Helius Medical financial indicator trend analysis is much more than just examining Helius Medical Techn latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Helius Medical Techn is a good investment. Please check the relationship between Helius Medical Price To Sales Ratio and its Free Cash Flow Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helius Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Price To Sales Ratio vs Free Cash Flow Per Share

Price To Sales Ratio vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Helius Medical Techn Price To Sales Ratio account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Helius Medical's Price To Sales Ratio and Free Cash Flow Per Share is -0.27. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Helius Medical Technologies, assuming nothing else is changed. The correlation between historical values of Helius Medical's Price To Sales Ratio and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Helius Medical Technologies are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Price To Sales Ratio i.e., Helius Medical's Price To Sales Ratio and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

-0.27

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Helius Medical Techn stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Helius Medical sales, a figure that is much harder to manipulate than other Helius Medical Technologies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from Helius Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Helius Medical Techn current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helius Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

At this time, Helius Medical's Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.02 in 2024, despite the fact that Enterprise Value is likely to grow to (225.7 K).

Helius Medical fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Other Liab	Long Term Debt	Net Receivables	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity
Common Stock Shares Outstanding		-0.19	-0.14	-0.15	-0.18	0.17	0.3	0.21	-0.18	-0.19	0.24	0.26	-0.14	-0.23	-0.17	0.15	0.24	-0.09	-0.07	-0.02	0.06	0.36	0.12	-0.09	-0.32	-0.31
Total Assets	-0.19		0.62	0.74	0.7	-0.98	-0.68	0.35	0.99	0.99	-0.18	0.59	0.77	0.71	0.99	0.53	-0.18	0.61	0.13	0.45	0.42	-0.72	-0.09	0.33	0.69	0.71
Total Current Liabilities	-0.14	0.62		0.02	-0.04	-0.68	-0.13	0.81	0.66	0.66	0.47	-0.01	0.9	0.39	0.64	0.71	0.47	0.98	-0.33	0.2	0.42	-0.24	0.16	0.17	0.06	0.05
Total Stockholder Equity	-0.15	0.74	0.02		0.89	-0.69	-0.62	-0.23	0.7	0.69	-0.7	0.58	0.14	0.45	0.71	0.17	-0.7	0.04	0.14	0.24	0.03	-0.63	-0.04	-0.01	0.74	0.79
Net Tangible Assets	-0.18	0.7	-0.04	0.89		-0.62	-0.79	-0.32	0.65	0.65	-0.7	0.69	0.19	0.6	0.68	0.09	-0.7	-0.03	0.51	0.55	0.2	-0.72	-0.47	0.12	0.89	0.86
Net Debt	0.17	-0.98	-0.68	-0.69	-0.62		0.55	-0.36	-1.0	-1.0	0.14	-0.51	-0.79	-0.59	-0.99	-0.62	0.14	-0.69	-0.07	-0.35	-0.31	0.6	-0.01	-0.36	-0.56	-0.6
Retained Earnings	0.3	-0.68	-0.13	-0.62	-0.79	0.55		-0.01	-0.59	-0.59	0.27	-0.77	-0.41	-0.92	-0.64	0.13	0.27	-0.02	-0.55	-0.81	-0.64	0.96	0.52	-0.33	-0.96	-0.94
Accounts Payable	0.21	0.35	0.81	-0.23	-0.32	-0.36	-0.01		0.35	0.35	0.8	0.06	0.73	0.36	0.35	0.52	0.8	0.72	-0.42	0.2	0.57	-0.13	0.25	0.09	-0.13	-0.11
Cash	-0.18	0.99	0.66	0.7	0.65	-1.0	-0.59	0.35		1.0	-0.16	0.53	0.79	0.62	1.0	0.6	-0.16	0.67	0.11	0.37	0.33	-0.63	-0.07	0.36	0.59	0.62
Cash And Short Term Investments	-0.19	0.99	0.66	0.69	0.65	-1.0	-0.59	0.35	1.0		-0.16	0.53	0.8	0.62	1.0	0.61	-0.16	0.67	0.11	0.37	0.33	-0.62	-0.07	0.36	0.59	0.61
Common Stock Total Equity	0.24	-0.18	0.47	-0.7	-0.7	0.14	0.27	0.8	-0.16	-0.16		-0.17	0.39	0.04	-0.15	0.15	1.0	0.38	-0.3	0.03	0.37	0.21	0.2	0.16	-0.48	-0.47
Other Current Assets	0.26	0.59	-0.01	0.58	0.69	-0.51	-0.77	0.06	0.53	0.53	-0.17		0.32	0.68	0.59	0.05	-0.17	-0.06	0.54	0.72	0.52	-0.7	-0.29	0.44	0.71	0.77
Total Liab	-0.14	0.77	0.9	0.14	0.19	-0.79	-0.41	0.73	0.79	0.8	0.39	0.32		0.63	0.8	0.62	0.39	0.86	0.05	0.43	0.58	-0.47	-0.09	0.49	0.31	0.29
Short Long Term Debt	-0.23	0.71	0.39	0.45	0.6	-0.59	-0.92	0.36	0.62	0.62	0.04	0.68	0.63		0.68	0.07	0.04	0.26	0.36	0.8	0.78	-0.91	-0.44	0.28	0.85	0.8
Total Current Assets	-0.17	0.99	0.64	0.71	0.68	-0.99	-0.64	0.35	1.0	1.0	-0.15	0.59	0.8	0.68		0.57	-0.15	0.64	0.15	0.44	0.39	-0.67	-0.1	0.38	0.64	0.66
Short Term Debt	0.15	0.53	0.71	0.17	0.09	-0.62	0.13	0.52	0.6	0.61	0.15	0.05	0.62	0.07	0.57		0.15	0.8	-0.3	-0.01	-0.05	0.05	0.2	0.0	-0.07	-0.08
Common Stock	0.24	-0.18	0.47	-0.7	-0.7	0.14	0.27	0.8	-0.16	-0.16	1.0	-0.17	0.39	0.04	-0.15	0.15		0.38	-0.3	0.03	0.37	0.21	0.2	0.17	-0.48	-0.47
Other Current Liab	-0.09	0.61	0.98	0.04	-0.03	-0.69	-0.02	0.72	0.67	0.67	0.38	-0.06	0.86	0.26	0.64	0.8	0.38		-0.34	0.1	0.26	-0.12	0.19	0.15	-0.02	-0.02
Other Liab	-0.07	0.13	-0.33	0.14	0.51	-0.07	-0.55	-0.42	0.11	0.11	-0.3	0.54	0.05	0.36	0.15	-0.3	-0.3	-0.34		0.57	0.29	-0.33	-0.78	0.61	0.5	0.43
Long Term Debt	-0.02	0.45	0.2	0.24	0.55	-0.35	-0.81	0.2	0.37	0.37	0.03	0.72	0.43	0.8	0.44	-0.01	0.03	0.1	0.57		0.8	-0.73	-0.6	0.3	0.72	0.69
Net Receivables	0.06	0.42	0.42	0.03	0.2	-0.31	-0.64	0.57	0.33	0.33	0.37	0.52	0.58	0.78	0.39	-0.05	0.37	0.26	0.29	0.8		-0.61	-0.33	0.34	0.49	0.48
Retained Earnings Total Equity	0.36	-0.72	-0.24	-0.63	-0.72	0.6	0.96	-0.13	-0.63	-0.62	0.21	-0.7	-0.47	-0.91	-0.67	0.05	0.21	-0.12	-0.33	-0.73	-0.61		0.36	-0.22	-0.93	-0.92
Short Term Investments	0.12	-0.09	0.16	-0.04	-0.47	-0.01	0.52	0.25	-0.07	-0.07	0.2	-0.29	-0.09	-0.44	-0.1	0.2	0.2	0.19	-0.78	-0.6	-0.33	0.36		-0.16	-0.52	-0.3
Non Current Liabilities Total	-0.09	0.33	0.17	-0.01	0.12	-0.36	-0.33	0.09	0.36	0.36	0.16	0.44	0.49	0.28	0.38	0.0	0.17	0.15	0.61	0.3	0.34	-0.22	-0.16		0.17	0.24
Capital Surpluse	-0.32	0.69	0.06	0.74	0.89	-0.56	-0.96	-0.13	0.59	0.59	-0.48	0.71	0.31	0.85	0.64	-0.07	-0.48	-0.02	0.5	0.72	0.49	-0.93	-0.52	0.17		0.95
Other Stockholder Equity	-0.31	0.71	0.05	0.79	0.86	-0.6	-0.94	-0.11	0.62	0.61	-0.47	0.77	0.29	0.8	0.66	-0.08	-0.47	-0.02	0.43	0.69	0.48	-0.92	-0.3	0.24	0.95

Click cells to compare fundamentals

Helius Medical Account Relationship Matchups

Helius Medical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	15.1K	24.0K	49.1K	269.9K	607.9K	577.5K
Total Assets	10.3M	6.5M	14.1M	17.3M	7.7M	9.9M
Total Current Liabilities	3.8M	2.4M	2.7M	2.0M	1.9M	1.8M
Total Stockholder Equity	5.8M	3.9M	11.3M	8.2M	2.4M	2.9M
Net Tangible Assets	4.0M	3.9M	10.2M	8.0M	9.2M	9.7M
Net Debt	(4.8M)	(3.2M)	(11.0M)	(14.4M)	(5.1M)	(5.4M)
Retained Earnings	(104.8M)	(118.9M)	(137.0M)	(151.1M)	(160.0M)	(152.0M)
Accounts Payable	1.7M	747K	1.1M	627K	531K	504.5K
Cash	5.5M	3.3M	11.0M	14.5M	5.2M	7.6M
Cash And Short Term Investments	5.5M	3.3M	11.0M	14.5M	5.2M	7.7M
Common Stock Total Equity	52.2M	26K	31K	1K	900.0	855.0
Liabilities And Stockholders Equity	10.3M	6.5M	14.1M	17.3M	7.7M	9.9M
Other Current Assets	610K	735K	862K	1.2M	1.0M	777.2K
Total Liab	4.5M	2.7M	2.8M	9.1M	5.3M	7.1M
Total Current Assets	7.2M	4.7M	12.6M	16.7M	7.4M	9.1M
Short Term Debt	172K	118K	6K	108K	90K	85.5K
Common Stock	26K	31K	1K	4K	28K	950.0
Other Current Liab	1.5M	1.3M	1.2M	1.2M	1.0M	994.7K
Net Receivables	574K	230K	251K	343K	637K	401.2K
Non Current Liabilities Total	710K	252K	193K	7.1M	3.5M	2.6M
Capital Surpluse	6.6M	105.4M	111.5M	123.9M	142.5M	149.6M
Other Stockholder Equity	111.5M	123.9M	149.4M	159.6M	163.0M	91.3M
Accumulated Other Comprehensive Income	(902K)	(1.1M)	(1.1M)	(388K)	(673K)	(706.7K)
Non Current Assets Total	3.1M	1.9M	1.5M	590K	254K	241.3K
Property Plant And Equipment Net	1.3M	576K	412K	450K	230K	418.2K
Net Invested Capital	5.8M	3.9M	11.3M	8.2M	2.4M	2.2M
Property Plant And Equipment Gross	1.3M	576K	412K	450K	589K	631.4K
Net Working Capital	3.4M	2.3M	9.9M	14.7M	5.6M	5.8M
Property Plant Equipment	1.3M	486K	412K	450K	517.5K	612.2K
Inventory	598K	389K	476K	589K	457K	531.9K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Helius Stock Analysis

When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC